Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a
bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a
variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic
benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the
IL13 receptors was shown to be highly specific for human glioma cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
INSYS Therapeutics Inc
Collaborator:
Pediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research Hospital